Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H

Lancet. 1988 Dec 17;2(8625):1394-9. doi: 10.1016/s0140-6736(88)90588-0.


A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Doses of 1-20 mg daily were given intravenously for up to 43 days. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. One patient had lymphadenopathy which also resolved. These effects were achieved without myelosuppression, and normal haemopoeisis was restored during the course of treatment, partially in one patient and completely in the other. No antiglobulin response was detected in either patient. CAMPATH-1H is a potent lympholytic antibody which might have an important use in the treatment of lymphoproliferative disorders and additionally as an immunosuppressive agent.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Anti-Idiotypic / analysis
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Female
  • Half-Life
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Remission Induction
  • Splenomegaly / therapy


  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal